...
search icon
avbp-img

ArriVent BioPharma, Inc. Common Stock, Common Stock

AVBP

NMQ

$20.81

-$0.49

(-2.3%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$712.23M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
90.31K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$15.47 L
$36.37 H
$20.81

About ArriVent BioPharma, Inc. Common Stock, Common Stock

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAVBPSectorS&P500
1-Week Return-0.53%-0.05%2.82%
1-Month Return25.29%3.02%12.33%
3-Month Return-28.85%-6.68%-6.28%
6-Month Return-34.93%-6.3%-1.77%
1-Year Return20.71%-2.03%9.69%
3-Year Return15.61%6.41%36.85%

Financials

Sep '21Sep '22Sep '23Sep '24
Total Revenue----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Cost of Revenue----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Profit----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Margin----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Operating Expenses8.70M36.91M74.59M94.31M[{"date":"2021-09-30","value":9.22,"profit":true},{"date":"2022-09-30","value":39.13,"profit":true},{"date":"2023-09-30","value":79.09,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Operating Income(8.70M)(36.91M)(74.59M)(94.31M)[{"date":"2021-09-30","value":-869600000,"profit":false},{"date":"2022-09-30","value":-3690600000,"profit":false},{"date":"2023-09-30","value":-7459000000,"profit":false},{"date":"2024-09-30","value":-9430800000,"profit":false}]
Total Non-Operating Income/Expense--10.51M27.64M[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":38.04,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Pre-Tax Income(51.61M)(36.91M)(69.33M)(80.49M)[{"date":"2021-09-30","value":-5160600000,"profit":false},{"date":"2022-09-30","value":-3690600000,"profit":false},{"date":"2023-09-30","value":-6933300000,"profit":false},{"date":"2024-09-30","value":-8048800000,"profit":false}]
Income Taxes(11.59M)(36.91M)-(80.49M)[{"date":"2021-09-30","value":-1159466400,"profit":false},{"date":"2022-09-30","value":-3690600000,"profit":false},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":-8048800000,"profit":false}]
Income After Taxes----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Income From Continuous Operations-(36.91M)(69.33M)(80.49M)[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":-3690600000,"profit":false},{"date":"2023-09-30","value":-6933300000,"profit":false},{"date":"2024-09-30","value":-8048800000,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(51.61M)(36.91M)(69.33M)(80.49M)[{"date":"2021-09-30","value":-5160600000,"profit":false},{"date":"2022-09-30","value":-3690600000,"profit":false},{"date":"2023-09-30","value":-6933300000,"profit":false},{"date":"2024-09-30","value":-8048800000,"profit":false}]
EPS (Diluted)---(2.66)[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":-266,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AVBP
Cash Ratio 12.67
Current Ratio 13.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AVBP
ROA (LTM) -26.91%
ROE (LTM) -39.36%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AVBP
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AVBP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.75
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is ArriVent BioPharma, Inc. Common Stock share price today?

ArriVent BioPharma, Inc. Common Stock (AVBP) share price today is $20.81

Can Indians buy ArriVent BioPharma, Inc. Common Stock shares?

Yes, Indians can buy shares of ArriVent BioPharma, Inc. Common Stock (AVBP) on Vested. To buy ArriVent BioPharma, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ArriVent BioPharma, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of ArriVent BioPharma, Inc. Common Stock (AVBP) via the Vested app. You can start investing in ArriVent BioPharma, Inc. Common Stock (AVBP) with a minimum investment of $1.

How to invest in ArriVent BioPharma, Inc. Common Stock shares from India?

You can invest in shares of ArriVent BioPharma, Inc. Common Stock (AVBP) via Vested in three simple steps:

  • Click on Sign Up or Invest in AVBP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ArriVent BioPharma, Inc. Common Stock shares
What is ArriVent BioPharma, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of ArriVent BioPharma, Inc. Common Stock (AVBP) is $36.37. The 52-week low price of ArriVent BioPharma, Inc. Common Stock (AVBP) is $15.47.

What is ArriVent BioPharma, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ArriVent BioPharma, Inc. Common Stock (AVBP) is 2.75

What is the Market Cap of ArriVent BioPharma, Inc. Common Stock?

The market capitalization of ArriVent BioPharma, Inc. Common Stock (AVBP) is $712.23M

What is ArriVent BioPharma, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of ArriVent BioPharma, Inc. Common Stock is AVBP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top